Nuevolution AB (publ) on 26 April 2018, announced that the company has obtained additional positive data from a pre-clinical mouse model supporting efficacy of its RORt candidate within inflammatory bowel diseases such as Crohn's disease and Ulcerative colitis. Nuevolution has previously presented positive preclinical data on its RORt candidate compound in two chemically induced preclinical models of IBD. In this new mouse study, colon inflammation and ulcerations were induced by adoptive transfer of pro-inflammatory T-cells from a healthy donor to an immune-compromised recipient unable to repress active T-cells, thereby inducing a clinical condition mimicking human IBD. The Nuevolution RORt candidate was tested in the challenging therapeutic setting, where treatment is initiated only following body weight loss and disease onset, requiring high compound efficacy to observe clinical improvement. The compound, dosed orally and twice daily at 30 or 100 mpk, gave a dose proportional improvement of the disease activity index as well as inflammation and ulceration to the colon. The clinical improvements observed using the RORt inhibitor at the highest dose, were either on par with, or superior to alternative treatment arms using either steroid or a neutralizing antibody targeting IL17A. These positive data, obtained from the benchmark preclinical model of IBD, are well in line with previous data from the chemical IBD models and provide additional support the efficacy of the RORt candidate compound and its potential future clinical application within IBD. The data will be further explained in the upcoming quarterly report being published May 8, 2018. As previously communicated, Nuevolution has recommended the arthritis type of disease termed Ankylosing spondylitis as the preferred initial clinical lead indication for its RORt program based on an expected overall lower risk in the clinical development.